Immunicum AB (publ) Announces Nomination Committee for AGM 2019
October 19 2018 - 2:00AM
Press Release
19 October 2018
Immunicum AB (publ) Announces Nomination Committee for AGM 2019
Immunicum AB
(publ) in accordance with the principles of appointing the
Nomination Committee, adopted by the Annual General Meeting of
April 25, 2018, announced today that the members of the Nomination
Committee have been appointed. The Nomination Committee for
Immunicum shall be appointed by the four largest shareholders as of
August 31, 2018 that have accepted the invitation to participate in
the committee.
The Chair of Immunicum's Board,
Michael Oredsson, has contacted major shareholders in order to
appoint a Nomination Committee.
The following members have been
appointed by the four largest shareholders that have accepted the
invitation to participate in the Nomination Committee:
Martin Lindström, appointed by Loggen
Invest AB, Chairman of the Nomination Committee
Bengt Andersson, appointed by Bengt Andersson
Ivar Nordqvist, appointed by Ivar Nordqvist
Jamal el-Mosel, appointed by BISP Invest AB
In total, the Nomination Committee
represents 9.2% of the total number of shares and votes in the
company.
The Annual General Meeting will be
held on the 25th of April 2019 in Stockholm.
Information about the work of the
Nomination Committee can be found at Immunicum's website
www.immunicum.com.
Shareholders wishing to make
proposals to the Nomination Committee should submit their proposal
in writing via email to martin@loggeninvest.se or by post to
Immunicum AB (publ), Att: Valberedningen, Grafiska Vägen 2, 412 63
Göteborg.
For more information, please contact:
Martin Lindström, Chairman of the
Nomination Committee
Telefon: +46 (0) 70 36 86 515
E-post: martin@loggeninvest.se
Michael Oredsson, Chairman of the
Board of Directors
Telephone: +46 70 718 89 30
Email: info@immunicum.com
About Immunicum AB (publ)
Immunicum is establishing a unique
immuno-oncology approach through the development of allogeneic,
off-the-shelf cell-based therapies. Our goal is to improve survival
outcomes and quality of life by priming the patient's own immune
system to fight cancer. The company's lead product ilixadencel,
consisting of pro-inflammatory allogeneic dendritic cells, has the
potential to become a backbone component of modern cancer
combination treatments in a variety of solid tumor indications.
Founded and based in Sweden, Immunicum is publicly traded on the
Nasdaq Stockholm www.immunicum.com
20181019_Immunicum AGM Nomination
Committee_ENG_Final
This
announcement is distributed by West Corporation on behalf of West
Corporation clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Immunicum AB via Globenewswire
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Mar 2024 to Apr 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Apr 2023 to Apr 2024